Key clinical point: A three-drug combination may improve response rates in high-risk CLL.
Major finding: The CR/CRi rate was 58.5%.
Study details: Prospective open-label phase 2 trial in 41 patients with CLL with del(17p) and/or TP53 mutations.
Disclosures: The trial was supported by Janssen-Cilag and Roche. Dr. Huber disclosed travel reimbursement from Novartis. Dr. Danilov disclosed consulting for AbbVie, Janssen, and Genentech.
Huber H et al. EHA Congress. Abstract S157.